Journal of Asthma and Allergy (Sep 2023)
Lung Function and Asthma Clinical Control in N-ERD Patients, Three-Year Follow-Up in the Context of Real-World Evidence
Abstract
Gandhi Fernando Pavón-Romero,1 Ramcés Falfán-Valencia,2 Katia Vanessa Gutiérrez-Quiroz,1 Estivaliz Arizel De La O-Espinoza,1 Nancy Haydée Serrano-Pérez,1 Fernando Ramírez-Jiménez,1 Luis M Teran1 1Department of Immunogenetics and Allergy, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; 2Laboratory of Human Leukocyte Antigen, Instituto Nacional de Enfermedades Respiratorias, Mexico City, MexicoCorrespondence: Luis M Teran, Department of Immunogenetics and Allergy, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Tlalpan, Mexico City, 14080, Mexico, Tel +52 5557481700 exr. 5162, Email [email protected]: To describe the lung function and clinical control of asthma in patients with N-ERD during three years of medical follow-up using GINA guidelines.Methods: We evaluated 75 N-ERD and 68 asthma patients (AG). Clinical control, lung function, and asthma treatment were evaluated according to GINA-2014. We compared all variables at baseline and one, two, and three years after treatment.Results: At baseline, the N-ERD group had better basal lung function (LF) than the AG group (p 0.05).Conclusion: According to GINA guidelines, only one-third of patients with N-ERD can gradually achieve adequate lung function and good asthma control with a high ICS dosage. Only a very small portion of patients will require the continued use of a second medication as an LTRA to keep their asthma under control.Keywords: N-ERD, asthma, severe asthma, corticosteroids, GINA guidelines, asthma clinical control
